§ 03 · The Biological Engine
Patented
methylglyoxal.
Engineered.
A proprietary mechanism engineered to completely shut down the evolvement of bacterial resistance.
§ 01
Targeted cell wall disruption
Methylglyoxal attacks the bacterial cell wall through a multi-site compositional mechanism that pathogens cannot route around.
§ 02
No observed evolutionary resistance
Across two decades of independent study, no resistance has been observed — a property without parallel among conventional antibiotics.
§ 03
Patented compositional structure
The engine is not a single molecule. It is a patented composition, protecting both the botanical matrix and the synthetic derivative.
§ 03.1 · De-risking matrix
Two parallel
assets.
Two independently patented compositions — one botanical, one synthetic — multiply delivery options and fundamentally de-risk capital across parallel clinical pathways. Both deploy the same patented composition of methylglyoxal.
§ Asset 01 · Botanical matrix
Lepto242
- Classification
- Botanical matrix
- Composition
- Patented natural composition of Medical Grade Manuka.
- Strategic advantage
- History of prior human use beginning in 1996, qualifying the 505(b)1 botanical pathway.
§ Asset 02 · Small molecule
Lgx242
- Classification
- Synthetic small molecule
- Composition
- Synthetic methylglyoxal derivative, engineered for precision delivery.
- Strategic advantage
- Highly targeted bio-defense delivery mechanisms, qualifying the QIDP / LPAD synthetic pathway.
§ 03.2 · Route 01
The
botanical
express lane.
The 505(b)1 botanical pathway, paired with a history of human use dating to 1996, delivers the speed and capital efficiency of a 505(b)2 — bypassing standard Phase 1 delays.
Estimated savings exceed ten million dollars and more than two years of clinical-trial overhead.
-
FDA Botanical Guidance
Codified regulatory framework for novel botanical therapeutics, distinct from the standard synthetic-drug pathway.
-
History of Human Use (1996)
Medical Grade Manuka has a continuous, documented history of human use since 1996, satisfying the prior-use requirement.
-
Express Lane equivalence
Together, these qualify Lepto242 for the speed and capital profile of a 505(b)2 application.
-
Precedent: Arikayce
Arikayce (Insmed Inc.) — an antibiotic with a nanocarrier for lung delivery — successfully bypassed Phase 1 trials under the same class of FDA framework.
§ 03.3 · Route 02
The
synthetic
fast track.
For Lgx242, two federal antimicrobial-resistance frameworks compound: QIDP under the GAIN Act grants five years of additional market exclusivity with automatic Fast Track status; the LPAD pathway scales trial burden to a limited, highly resistant patient population.
Together, these compress the approval timeline while preserving full commercial exclusivity.
§ QIDP · GAIN Act
+5 years exclusivity
Qualified Infectious Disease Product designation under the GAIN Act secures five additional years of market exclusivity on top of the base term, and automatically unlocks Fast Track review.
§ LPAD pathway
Limited Population Approval
Limited Population for Antimicrobial Drugs bypasses the three-thousand-subject statistical threshold: efficacy is proven on a small, highly resistant cohort, compressing timeline and cost.
§ 03.4 · Convergence
Strategic
asymmetry.
Biological efficacy fused with expedited FDA pathways creates a highly asymmetric upside. Three vectors compound around a single patented engine.
§ 01
Deep biological efficacy
Methylglyoxal destroys superbugs via mechanisms that remain unopposed by known resistance pathways.
§ 02
Regulatory fast-tracking
The GAIN Act, LPAD, and Botanical Guidance jointly bypass years of clinical delay and mitigate trial cost.
§ 03
Capital efficiency
Multiple shots on goal via parallel routes ensure early funding achieves compounding milestones, de-risking sequential capital raises.
§ 03.5 · Catalyst
A $500K
capital bridge.
A foundation catalyst of five hundred thousand dollars de-risks the subsequent one-point-five-million-dollar raise, satisfying baseline FDA toxicity requirements and proving a safe, effective solution prior to Series A.
§ Efficacy validation
$60–80K · MicroChem Labs
In-vitro testing against the World Health Organization list of multi-drug-resistant bacteria, establishing a disease-agnostic efficacy profile.
§ Safety validation
$380–420K · Charles River
Formal preclinical toxicology program at Charles River Laboratories to satisfy the FDA prerequisite dossier for IND progression.
The catalyst, a $500,000 foundation, de-risks the next $1,500,000 — a $2.0 million capital raise that protects shareholder value through Series A.
§ Continue